Portfolio companies news

22 October 2013

Regado Biosciences Selects TransPerfect’s Trial Interactive Platform as its Study Start-Up and eTMF Solution

Solution Enables Regado Biosciences to Streamline 500-Site Global Study.

21 October 2013

ReVision Optics – 2013 Fierce 15

FierceMedicalDevices

ReVision Optics is upping the technological game with vision improvement devices and technology. The company's Raindrop Near Vision microscopic hydrogel inlay is designed to treat patients with presbyopia, the loss of near vision in patients when they reach middle age and typically need reading glasses. CEO John Kilcoyne said doctors can now also use RainDrop in patients receiving a separate procedure to correct their distance vision.

FierceMedicalDevices' 2013 Fierce 15

Mark Hollmer, FierceMedicalDevices

This year's crop endured the struggles many startups face and came out ahead. They've attracted substantial funding from major investors in a tough market, proving the worth of their products. Many are also already in--or close to--market with their signature products, a sign of stability that draws investor commitments much more these days than companies on the earlier side of development.

11 October 2013

Syndax Names Steven M. Fruchtman, M.D., Chief Medical Officer

Syndax Pharmaceuticals Inc. today announced the appointment of Steven M. Fruchtman, M.D., a hematologist/oncologist with extensive experience in early and late-stage drug development with biopharmaceutical companies and in clinical practice, as chief medical officer.

03 October 2013

NovaDigm Therapeutics Raises $14M Series B to Support Phase 2 Trial of NDV-3 Vaccine

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that it has closed a $14M Series B financing. 

01 October 2013

Lithera Reports Positive Clinical Study Results From Its Phase 2b RESET Trial for LIPO-202, a Novel Treatment for Abdominal Body Contouring

Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today announced positive results from its Phase 2b RESET clinical study of LIPO-202 (Salmeterol Xinafoate for Injection). 

30 September 2013

Syndax scores a coveted 'breakthrough' designation for PhIII cancer drug

John Carroll, FierceBiotech

Syndax Pharmaceuticals has scored a rare win for a small, private biotech, snagging the FDA's breakthrough designation for a Phase III-ready breast cancer therapy just days after rolling up a $27 million venture round.

26 September 2013

NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the initiation of a Phase 1b/2a clinical trial to evaluate its NDV-3 vaccine in preventing episodes of vulvovaginal candidiasis (VVC) in patients with recurrent VVC (RVVC). 

Hydrogel inlay improves uncorrected near visual acuity in presbyopic emmetropic eyes

Matt Hasson, Ocular Surgery News U.S. Edition

The inlay creates multifocality at the corneal plane, with near vision on the visual axis and a transition to intermediate, distance vision out to the periphery.

17 September 2013

Regado Biosciences, Inc. enrolls first patient in phase 3 trial of REG1

Regado Biosciences, Inc., a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications, today announced the enrollment of the first patient in its REGULATE-PCI clinical trial.